Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Linda Ashcroft
Comprehensive CYP2D6 Genotype and Adherence Affect Outcome in Breast Cancer Patients Treated With Tamoxifen Monotherapy
Breast Cancer Research and Treatment
Cancer Research
Oncology
Related publications
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated With Tamoxifen
Frontiers in Pharmacology
Pharmacology
Prevalent Breast Cancer Patients With a Homozygous Mutant Status for CYP2D6*4: Response and Biomarkers in Tamoxifen Users
Breast Cancer Research and Treatment
Cancer Research
Oncology
CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality
Clinical Pharmacology and Therapeutics
Pharmacology
Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients
Journal of Clinical Pharmacology
Pharmacology
TSC22D1 and PSAP Predict Clinical Outcome of Tamoxifen Treatment in Patients With Recurrent Breast Cancer
Breast Cancer Research and Treatment
Cancer Research
Oncology
CYP2D6 Genotyping and Tamoxifen in the Treatment of Post-Menopausal Breast Cancer - A Reply
British Journal of Clinical Pharmacology
Pharmacology
Pcn191 - Cost-Effectiveness of Monitoring Endoxifen Levels in Breast Cancer Patients Adjuvantly Treated With Tamoxifen
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Limited Predictive Value of Achieving Beneficial Plasma (Z)-Endoxifen Threshold Level by CYP2D6 Genotyping in Tamoxifen-Treated Polish Women With Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
T Cells Predict Outcome in Zoledronate-Treated Breast Cancer Patients
Oncologist
Cancer Research
Medicine
Oncology
